Patient P-01482
Therapy response
Declining
Tolerance
Improving
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
72%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 51 GI-04 recommended — GI Support Protocol GI-04
- Day 52 Patient accepted — Started GI-04 in the companion
- Day 60 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 66 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- Toxicity-10
- Nutritional resilience-3
- GI instability+2
- Inflammatory activity-2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −12%
- GI Support Protocol GI-04Day 51Result: symptom burden −19%
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 57
- WearableHRV 22 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 75 bpm
- Wearable1,440 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓30
- Daily logGI symptom score 54 and rising
- WearableSleep 5.8 h, below personal baseline
- Drug metabolism and exposure ↑20
- BloodToxicity index 51
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.7 · butyrate capacity 28/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 27 ms
- Sleep
- 6.3 h
- Steps
- 1,112
- Resting HR
- 74 bpm
Daily log: GI score 54, nutritional resilience 39, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 20% | S19 | AD-05 | improved | 61 |
| P-01696 | 29% | S20 | CR-01 | improved | 59 |
| P-01708 | 28% | S07 | CR-01 | improved | 59 |
| P-01835 | 27% | S17 | CR-01 | improved | 56 |
| P-01371 | 26% | S06 | CR-01 | improved | 63 |
| P-01388 | 26% | S17 | CR-01 | improved | 59 |
| P-01442 | 26% | S13 | CR-01 | improved | 61 |
| P-01877 | 26% | S01 | CR-01 | improved | 67 |
| P-01430 | 21% | S05 | CR-01 | improved | 54 |
| P-01342 | 19% | S11 | DT-01 | improved | 48 |
| P-01454 | 55% | S14 | GI-04 | no change | 49 |
| P-01595 | 52% | S14 | GI-04 | no change | 51 |